Quintiles dishes on vaccine R&D; Novo nears IT spinoff;

> Quintiles ($Q) testified before Congress about the long, expensive process of vaccine development and suggested potential policy pathways that accelerate R&D. News

> Novo Nordisk ($NVO) is gearing up to spin out its pharma IT business, NNIT, in the coming week, launching an independent contractor that will seek to do business with its parent company's rivals. Story

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.